HLA-C and neoplasm: High TMB is consistently used to select proper patients for ICI therapy because somatic mutations in tumor DNA may have a chance to produce neoantigen-containing peptides, which can be processed, displayed onto major histocompatibility complex (MHC) molecules, and recognized by T cells.